Bayer and CrossBay Medical today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.
The partnership will result in the further development and expansion of CrossBay’s existing CrossGlide technology. The CrossGlide technology has the potential to substantially improve the intrauterine placement experience by limiting and reducing the discomfort some women may experience during IUS insertion. By removing these steps, the inserter also has the potential to reduce procedure time necessary for healthcare professionals.
“As a leader in Women’s Healthcare, we are committed to further drive innovation for women worldwide that addresses their unmet medical needs,” said Juergen Eckhardt, M.D., Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of Business Development, Licensing & Open Innovation. “Partnering with CrossBay Medical has the potential to offer women an opportunity to consider the full range of contraceptive options available.”
“We invented CrossGlide to help improve the insertion experience by creating a flexible system that follows the shape of a woman’s cervix. By doing this, we created a new paradigm for office-based procedures for both women and healthcare providers,” said Piush Vidyarthi, founder and CEO of CrossBay Medical, Inc. “We are partnering with Bayer as a market leader in intrauterine contraception as we believe more women will be better served using the CrossGlide technology and therefore provided one of the most effective birth control options for consideration.”
Pairing CrossBay’s technology with Bayer’s leading IUS portfolio will also result in adapting the manufacturing process and industrialization of the CrossGlide technology, building on Bayer’s expertise in the field specifically at the company’s state-of-the art production site in Turku, Finland.